DLA Piper advises ASP Isotopes on Strategic Relationship with PET Labs

DLA Piper has advised NASDAQ listed ASP Isotopes, a developer of technology and processes which produces isotopes for use in multiple industries, on its strategic relationship with PET Labs.

PET Labs is a Pretoria based South African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production. It focuses on the production of fluorinated radioisotopes and active pharmaceutical ingredients.

This strategic relationship will help both companies boost their company growth over the next few years ensuring a stable supply of PET and SPECT radioisotopes to Southern African and developing world markets.

The DLA Piper team was led by Johannesburg based Corporate director, André Visser with support from Associate Zama Shoba.

André Visser commented: “We were delighted to support ASP Isotopes on their strategic relationship with PET Labs in South Africa, in this very specialised area of nuclear medicine. There is a clear need for additional radioisotope production capability in Sub Saharan Africa and we look forward to supporting both companies as they bring new treatments to patients in frontier markets” .